Study Investigating Oral JAK Inhibitor for Alopecia Areata Meets Endpoint

Positive topline results were announced from a second phase 3 trial evaluating CTP-543 in adults with moderate to severe alopecia areata.

Related Keywords

Jamesv Cassella , ,Company New Drug Application ,Concert Pharmaceuticals ,Drug Administration ,Alopecia Tool ,New Drug Application ,Chief Development Officer ,